Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zenabis Global Inc. T.ZENA

We are a diverse, passionate team of doctors, scientists, researchers, growers, educators, and advocates who came together with the goal of increasing access to safe, high quality cannabis for medical patients and recreational consumers. Our four facilities are located coast-to-coast across Canada in Delta and Langley, British Columbia; Atholville, New Brunswick; and Stellarton, Nova Scotia. Zenabis currently owns 3.5 million square feet of facility space.


TSX:ZENA - Post by User

Comment by Zaybureon Dec 21, 2020 11:37am
197 Views
Post# 32152789

RE:The Zenabis update ...may... be pretty darn good

RE:The Zenabis update ...may... be pretty darn good
StoneMan45 wrote: https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00007772

yes they are saying it is possible that the heightened covid may(as it may interupt their rapidly increasing sales but then again it may not) impact q4 guidence slightly but it is still a very good gain . 


The Company is expecting record monthly sales into Alberta in the month of December and sales continue to trend upwards in all of the nine provinces and three territories where our products are listed. The implementation of COVID-19-related lock-downs and other restrictions in the Company’s key markets during the fourth quarter of 2020; however, may temporarily interrupt this upwards sales trend and the Company is accordingly revising its consolidated net revenue guidance for Q4 2020 to $22 million to $27 million comprised of $16 million to $19 million for the Cannabis segment and $6 million to $8 million for the Propagation segment. Consolidated adjusted EBITDA for the quarter is now expected to be $3 million to $5 million. Sales of pre-rolls continue to grow with month-over-month sales increasing 9% on average for this category, for the eleven completed months of 2020, and 13% month-over-month growth over the last three months.


Don't know if this is to lower expectation, nevertheless it's positive news as a whole.

In the price action this morning, very little movement from last week: the Bid price (.045) stands at 10M shares while the Ask price (.05) is in the 1.5M shares range.

<< Previous
Bullboard Posts
Next >>